Table 1 Baseline characteristics
Characteristic, n (%) | Intention-to-treat population (n = 64) |
|---|---|
Gender | |
 Male | 49 (76.6) |
 Female | 15 (23.4) |
Age, median (IQR), years | 44 (39–54) |
Histology | |
 WHO I/II | 8 (12.5) |
 WHO III | 56 (87.5) |
ECOG performance status | |
 0 | 29 (45.3) |
 1 | 19 (29.7) |
 2 | 16 (25.0) |
Recurrence and/ or metastasis | |
 Recurrence | 5 (7.8) |
 Metastasis | 44 (68.8) |
 Recurrence and metastasis | 15 (23.4) |
Involved metastatic organs | |
 Single | 28 (43.8) |
 Multiple | 31 (48.4) |
Location of metastases | |
 Liver | 30 (46.9) |
 Lung | 26 (40.6) |
 Bone | 22 (34.4) |
 Others | 24 (37.5) |
Target lesion size, median (IQR), mm | 47 (33–79) |
Plasma EBV DNA level, median (IQR), copies/mL | 3915 (422–32,500) |
No. of previous treatment | |
 1 | 38 (59.4) |
 2 | 12 (18.8) |
 ≥ 3 | 14 (21.9) |
Previous PD-1/PD-L1 inhibitor treatment | |
 Yes | 23 (35.9) |
 No | 41 (64.1) |